Arcus Biosciences Inc. (RCUS)
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
📉 **NEGATIVE** • Medium confidence analysis (79%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (5%) **Content type:** Clinical